Product Images Tamsulosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Tamsulosin Hydrochloride NDC 68071-2561 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

pdp - 68071 2561 9

pdp - 68071 2561 9

This is a description of medication packaging from NuCare Pharmaceuticals, Inc. The medication is Tamsulosin Hydrochloride in capsule form with a dosage of 0.4mg. The package contains 90 capsules and each capsule contains Tamsulosin Hydrochloride. The capsules are olive green opaque and orange opaque with an imprint of 'D' on the cap and 53 on the body. The lot number for the capsules is 00000 and the expiration date is 00-00. The medication should be stored at a controlled temperature of 68-77°F and kept out of reach of children. If you experience any side effects with this medication, you should contact your doctor or call 1-800-FDA-1088.*

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

The text appears to be a figure caption for a graph depicting the mean plasma concentrations of Tamsulosin Hydrochloride capsules administered at 0.4 mg under fasted and fed conditions. The figure also includes a time axis.*

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

Figure 2A	Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

A graph is shown in Figure 2A depicting the mean change from baseline in Total AUA Symptom Score ranging from 0 to 35 from Study 1. The treatment groups involved were -OO-0-08mg_~A= A -A04my_ and O30 Placebo. The duration of treatment ranged from 1 to 13 weeks with varying sample sizes.*

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 2B	Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 2B shows the mean change in Total American Urological Association (AUA) Symptom Score from baseline on different treatment protocols. The treatments compared include 0.08mg and 0.4mg LNt, and Placebo. The study lasted for up to 13 weeks. The figure provides information of the number of participants in each group and the time frame of the study.*

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

This is a graph (Figure 3A) that shows the mean increase in peak urine flow rate (in L/sec) in Study 1. The treatments 0.08mg and 0.4mg are compared to a placebo, with the mean change in urine flow rate (in mL/sec) shown on the vertical axis. The duration of treatment (in weeks) is shown on the horizontal axis. There are different sample sizes for each treatment group.*

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Chemical Structure - tamsulosin str

Chemical Structure - tamsulosin str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.